

Electronic Acknowledgement Receipt

EFS ID:	6082311
Application Number:	10701007
International Application Number:	
Confirmation Number:	5641
Title of Invention:	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
First Named Inventor/Applicant Name:	Charles Allerson
Customer Number:	32650
Filer:	Jane E. Inglese/Judith Komala
Filer Authorized By:	Jane E. Inglese
Attorney Docket Number:	ISIS-5325
Receipt Date:	16-SEP-2009
Filing Date:	04-NOV-2003
Time Stamp:	12:59:28
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Manoharan_BiochimBiophysActa_117-130.PDF	1191162 b7bedb2b6fd78053b29f405d7b161697e0b96c3ef	no	14

Warnings:

Information:

2	NPL Documents	Manoharan_DesignerAntisense Oligonucleotides_303-349.PDF	3478312 11a3d9fed9c260b5c110edf77511c269d05d c75e4	no	50
Warnings:					
Information:					
3	NPL Documents	Manoharan_AntisenseNucleicA cidDrugDevelopment_103-128. PDF	518590 624edfd136d56a13f8bd4db6a13810702ce 06d29e	no	26
Warnings:					
Information:					
4	NPL Documents	Manoharan_AntisenseDrugTec hnologyPrinciplesStrategisand Applications_391-467.PDF	7203252 dfc5b6cc06f8f71991a002134f81364a87d8c 3049	no	39
Warnings:					
Information:					
5	NPL Documents	Manoharan_CurrOpinChemBiol _2004_570-579.PDF	865749 21ed3027b20bbce0ac1a0dc0d0776aed60d bbdf7	no	10
Warnings:					
Information:					
6	NPL Documents	Marcus- Sekura_NuclAcidsRes_5749-57 63.PDF	1059573 70e7c25abe081e3e6e872913c06e8e862d7 801	no	15
Warnings:					
Information:					
7	NPL Documents	Marcus- Sekura_AnalBiochem_289-295. PDF	572026 c165d4191d0e186de138fd7aa7ee5c13dd 105d	no	7
Warnings:					
Information:					
8	NPL Documents	Markiewicz_NucleicAcidChemis try_229-231.PDF	331980 0dc5d7d6f1c159d93dc67a06c92678b12c edc	no	4
Warnings:					
Information:					
9	NPL Documents	Maruenda_BioconjugateChem _541-544.PDF	425919 60e67534b90290ce13dbd717abcc0e6e8f75 7f0e	no	4
Warnings:					
Information:					
10	NPL Documents	Maruenda_AntiCancerDrugDes _473_479.PDF	425272 38ec278baef430ba0000708243d45485177 330e	no	7
Warnings:					
Information:					

11	NPL Documents	Marwick_JAmMedAssoc_1998-871.PDF	243249 e602eb1da8b13e91d51bca9953ed1c559a3de	no	1
Warnings:					
Information:					
12	NPL Documents	Maskos_NuclAcidsRes_1679-1684.PDF	697329 eef5a26a9b1079d1d4b0602e95197b5c7b2c4e0da	no	6
Warnings:					
Information:					
13	NPL Documents	Matson_AnalBiochem_1994_306-310.PDF	549556 a7d1997b61cfcac7b091c1317946a078a1ecccdd12	no	5
Warnings:					
Information:					
14	NPL Documents	Matsukura_PNAS_1987_7706-7710.PDF	512594 bb135861d7081613001e6285a13c18fedf0c0ebd	no	5
Warnings:					
Information:					
15	NPL Documents	Matteucci_JAmChemSoc_3185-3191.PDF	793464 abdc07c0d81dc95149327991b1c25db5a89a99	no	7
Warnings:					
Information:					
16	NPL Documents	McBride_TetrahedLetts_245-248.PDF	278570 91e17497b0d3fca2d34d9c7b0d9927d03be9db7	no	4
Warnings:					
Information:					
17	NPL Documents	McCafferey_Nature_38-39.PDF	386547 8a5d0c0b7c75195e4978f961c28ec11024a1f10	no	2
Warnings:					
Information:					
18	NPL Documents	McIntyre_AntisenseResDev_309-322.PDF	1262787 37ad518bd76ed2b73eca07c5e341354705835	no	14
Warnings:					
Information:					
19	NPL Documents	McQueen_CellBioToxicol_201-206.PDF	408485 6c7f153d57d2982aa27371c61581bf1f9aeef99	no	6
Warnings:					
Information:					

20	NPL Documents	Meegan_Science_1989_1089-1091.PDF	404027 0608a411b84c615a060801e41381b5c24b54ed3	no	3
Warnings:					
Information:					
21	NPL Documents	Metelev_BioorgMedChemLett_2929-2934.PDF	301182 4204c985dbcc22226d497f1f512af0ee3b4b2	no	6
Warnings:					
Information:					
22	NPL Documents	Meunier_NuclAcidRes_2730-2736.PDF	1265846 0084cf15c07380984584ab21c4ab22773b120151	no	7
Warnings:					
Information:					
23	NPL Documents	Meyer_JAmChemSoc_8517-8519.PDF	485706 a1327bb03694a644531268294736007c29bb7c7	no	3
Warnings:					
Information:					
24	NPL Documents	Mili_MolCellBiol_7307-7319.PDF	593667 4b51c16d75a941313702be07b7c2f2ceb54608b	no	13
Warnings:					
Information:					
25	NPL Documents	Miller_AntiCancDrugDes_117-128.PDF	784745 606d6b3c494df6b5150aacd113b77f719930137	no	12
Warnings:					
Information:					
26	NPL Documents	Miller_Biochemistry_1874-1880.PDF	796147 5081d952920204c7c0249eb500acda7ed822d8b	no	7
Warnings:					
Information:					
27	NPL Documents	Miller_Biochemistry_5134-5143.PDF	1139172 dae42af26ce02054e0bce1fa2491e46e7c4db1	no	10
Warnings:					
Information:					
28	NPL Documents	Miller_JAmChemSoc_6657-6664.PDF	912527 d315488b964953d4d63b7bdf91913ae0527bd1	no	9
Warnings:					
Information:					

29	NPL Documents	Milligan_JMedChem_1993_1923-1937.PDF	1980567 7921bda73f23c7339401e6ccc2f6d35a2f9a91	no	15
Warnings:					
Information:					
30	NPL Documents	Min_BioorgMedchemLett_2002_2651-2654.PDF	467037 7ca0377a7501222d6db508b869ca3bc5153da09	no	4
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
31	NPL Documents	Mishra_BiochimBiophysActa_229-237.PDF	901427 416c508bacc1-0374cc813118f3c3d52-ff9abcc786	no	9
Warnings:					
Information:					
32	NPL Documents	Miura_ClinChem_1996_1758-1764.PDF	612820 27cac0f7f62f5576cc82970f8baced6059ada	no	7
Warnings:					
Information:					
33	NPL Documents	Monia_NatMed_668-675.PDF	991344 8a3fd2d6096d118a08bee0715aefcc6ff3da09	no	8
Warnings:					
Information:					
34	NPL Documents	Monia_JBiolChem_14514-14522.PDF	1409626 86e795f77f9e8a17d86c3f66136d119af6d68e	no	9
Warnings:					
Information:					
35	NPL Documents	Monia_JBiolChem_1992_19954-19962.PDF	1229864 9cd21142a902a737ad7941ed6e93aed5d199dd	no	9
Warnings:					
Information:					
36	NPL Documents	Montgomery_PNAS_1998_15502-15507.PDF	857674 b113bcad6a2d5380d27dd6ff0295884ef1f2	no	6
Warnings:					
Information:					
37	NPL Documents	Moran_PNAS_10506-10511.PDF	192331 925e38448c540d49faffa3b85668530713d8c11	no	6

Warnings:**Information:**

38	NPL Documents	Moran_JAmChemSoc_2056-2057.PDF	126455	no	2
			9da5543c77903e190a8c2b2e2f1e5d0951d4e1e		

Warnings:**Information:**

Total Files Size (in bytes):	36656580
------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.